ALLR Allarity Therapeutics, Inc. Stock Quote

ALLR [NASD]

Index	-	P/E	-	EPS (ttm)	-3.87	Insider Own	19.87%	Shs Outstand	8.29M	Perf Week	-31.52%
Market Cap	11.92M	Forward P/E	-	EPS next Y	-1.02	Insider Trans	0.00%	Shs Float	7.44M	Perf Month	-57.86%
Income	-	PEG	-	EPS next Q	-0.42	Inst Own	3.70%	Short Float	0.41%	Perf Quarter	-42.73%
Sales	-	P/S	-	EPS this Y	-412.60%	Inst Trans	-	Short Ratio	0.21	Perf Half Y	-88.11%
Book/sh	1.78	P/B	0.71	EPS next Y	45.20%	ROA	-	Target Price	8.00	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	1.10 - 18.20	Perf YTD	-87.85%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-93.30%	Beta	-
Dividend %	-	Quick Ratio	1.40	Sales past 5Y	-	Gross Margin	-	52W Low	10.91%	ATR	0.27
Employees	13	Current Ratio	1.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	34.23	Volatility	14.04% 11.98%
Optionable	No	Debt/Eq	0.07	EPS Q/Q	-172.60%	Profit Margin	-	Rel Volume	0.55	Prev Close	1.26
Shortable	Yes	LT Debt/Eq	0.07	Earnings	-	Payout	-	Avg Volume	147.15K	Price	1.22
Recom	1.00	SMA20	-32.03%	SMA50	-33.13%	SMA200	-71.20%	Volume	6,553	Change	-3.17%

Jun-29-22 04:01PM	Allarity Therapeutics Announces Executive Leadership Transition GlobeNewswire -11.41%
Jun-15-22 09:25AM	Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D. GlobeNewswire
May-27-22 05:37PM	Allarity Therapeutics Reports First Quarter 2022 Financial Results GlobeNewswire +39.32%
May-18-22 05:30PM	Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update GlobeNewswire
May-16-22 07:40PM	Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update GlobeNewswire
Apr-22-22 05:00PM	Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) GlobeNewswire
Mar-15-22 08:32AM	Allarity Therapeutics Provides Update on Dovitinib Program GlobeNewswire
Feb-18-22 04:15PM	Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA GlobeNewswire
Jan-21-22 02:30AM	Nasdaqs European Markets Delivered Record Year in 2021 GlobeNewswire
Jan-03-22 08:00AM	Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib GlobeNewswire
Dec-22-21 08:00AM	Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC) GlobeNewswire +20.24%
Dec-21-21 08:00AM	Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market GlobeNewswire

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience